Masimo

Politan Comments on Masimo’s Latest Attempt to Block a Fair Shareholder Vote

Retrieved on: 
Sunday, September 15, 2024
Professional Services, Finance, Security (finance), Person, Masimo, Common stock, Court, Annual general meeting, ANY, Common, MASI, ARE, Contempt, INC, Record, WALL

Notably, Masimo has still not even made the Court’s orders readily accessible for shareholders and instead has issued multiple misleading press releases.

Key Points: 
  • Notably, Masimo has still not even made the Court’s orders readily accessible for shareholders and instead has issued multiple misleading press releases.
  • Politan does not make any representations regarding the accuracy, completeness or timeliness of such third party statements or information.
  • The participants in the proxy solicitation are Politan, Politan Capital Management GP LLC (“Politan Management”), Politan Capital Partners GP LLC (“Politan GP”), Politan Capital NY LLC (the “Record Stockholder”), Politan Intermediate Ltd., Politan Capital Partners Master Fund LP (“Politan Master Fund”), Politan Capital Partners LP (“Politan LP”), Politan Capital Offshore Partners LP (“Politan Offshore” and, collectively with Politan Master Fund and Politan LP, the “Politan Funds”), Quentin Koffey, Matthew Hall, Aaron Kapito (all of the foregoing persons, collectively, the “Politan Parties”), William Jellison and Darlene Solomon (such individuals, collectively with the Politan Parties, the “Participants”).
  • As the general partner of Politan, Politan Management may be deemed to have the shared power to vote or direct the vote of (and the shared power to dispose or direct the disposition of) all of the Politan Group Shares and, therefore, Politan Management may be deemed to be the beneficial owner of all of the Politan Group Shares.

Masimo Issues Statement Following Court’s Order Holding Politan and Quentin Koffey in Contempt and Finding Politan Made False Statements to Stockholders

Retrieved on: 
Saturday, September 14, 2024
Medical Devices, Hardware, Health, Technology, Health Technology, Egan-Jones Ratings Company, Glass, Patient, Masimo, Court, Annual general meeting, Corporation, MASI, Hearing, District court, Contempt, ISS, GOLD, Thought

In its ruling on Masimo’s motion, which has now been made public, the Court also found that Politan and Quentin Koffey actively and repeatedly disseminated materially false and misleading statements to Masimo stockholders.

Key Points: 
  • In its ruling on Masimo’s motion, which has now been made public, the Court also found that Politan and Quentin Koffey actively and repeatedly disseminated materially false and misleading statements to Masimo stockholders.
  • The Court’s ruling confirms that Quentin Koffey and Politan, who are seeking control of Masimo, have been dishonest with stockholders.
  • The Company stated, “Today’s rulings further validate our view that Politan and Quentin Koffey are not qualified to lead Masimo.
  • In contrast, Masimo has always acted with integrity, keeping the best interests of patients and stockholders at the forefront of our thinking.

Politan Issues Statement From Legal Advisors Schulte Roth & Zabel and Munger, Tolles & Olson Regarding Masimo Proxy Contest

Retrieved on: 
Friday, September 13, 2024
Professional Services, Finance, Person, Annual general meeting, Common, INC, Prejudice, Security (finance), Common stock, MASI, ARE, Record, Court, ANY, Comment, Motion, WALL, Masimo, Schulte Roth & Zabel

If you have any questions, require assistance in voting your

Key Points: 
  • If you have any questions, require assistance in voting your
    WHITE universal proxy card or voting instruction form,
    or need additional copies of Politan’s proxy materials,
    please contact D.F.
  • Politan does not make any representations regarding the accuracy, completeness or timeliness of such third party statements or information.
  • The participants in the proxy solicitation are Politan, Politan Capital Management GP LLC (“Politan Management”), Politan Capital Partners GP LLC (“Politan GP”), Politan Capital NY LLC (the “Record Stockholder”), Politan Intermediate Ltd., Politan Capital Partners Master Fund LP (“Politan Master Fund”), Politan Capital Partners LP (“Politan LP”), Politan Capital Offshore Partners LP (“Politan Offshore” and, collectively with Politan Master Fund and Politan LP, the “Politan Funds”), Quentin Koffey, Matthew Hall, Aaron Kapito (all of the foregoing persons, collectively, the “Politan Parties”), William Jellison and Darlene Solomon (such individuals, collectively with the Politan Parties, the “Participants”).
  • THE DEFINITIVE PROXY STATEMENT AND OTHER RELEVANT DOCUMENTS ARE ALSO AVAILABLE ON THE SEC WEBSITE, FREE OF CHARGE, OR BY DIRECTING A REQUEST TO THE PARTICIPANTS’ PROXY SOLICITOR, D.F.

Masimo’s Lawsuit Forced Politan and Quentin Koffey to Issue Corrective Disclosures on False and Misleading Statements Made to Masimo Stockholders on Issues Material to the Proxy Contest

Retrieved on: 
Thursday, September 12, 2024
Biotechnology, Medical Devices, Biometrics, Health, Health Technology, Committee, Masimo, Corporation, Glass Lewis, MASI, Hearing, District court, Spin, ISS, Risk, Sale, GOLD

Masimo’s lawsuit forced Politan to issue several new disclosures, including on the morning of the hearing, to correct its false and misleading statements and to provide material information Politan previously concealed from Masimo stockholders, ISS and Glass Lewis.

Key Points: 
  • Masimo’s lawsuit forced Politan to issue several new disclosures, including on the morning of the hearing, to correct its false and misleading statements and to provide material information Politan previously concealed from Masimo stockholders, ISS and Glass Lewis.
  • These false and misleading statements include:
    Politan and Quentin Koffey Lied About the Spin-off.
  • Mr. Koffey falsely claimed that the Special Committee had unanimously rejected the term sheet he had previously agreed upon with Mr. Kiani.
  • In fact, Politan’s corrective disclosures revealed that Mr. Koffey never shared the agreed upon term sheet with any other member of the Special Committee.

Politan Comments on Judge’s Decision to Deny Masimo’s Request for a Preliminary Injunction

Retrieved on: 
Thursday, September 12, 2024
Asset Management, Legal, Professional Services, Finance, Person, Annual general meeting, Common, Motion, Delaware Court, INC, Security (finance), Centerview Partners, Common stock, MASI, ARE, Record, ANY, WALL, Masimo, RTW

Politan produced more than 17,500 documents and more than 97,500 pages of materials in response to the Company’s aggressive discovery requests.

Key Points: 
  • Politan produced more than 17,500 documents and more than 97,500 pages of materials in response to the Company’s aggressive discovery requests.
  • The participants in the proxy solicitation are Politan, Politan Capital Management GP LLC (“Politan Management”), Politan Capital Partners GP LLC (“Politan GP”), Politan Capital NY LLC (the “Record Stockholder”), Politan Intermediate Ltd., Politan Capital Partners Master Fund LP (“Politan Master Fund”), Politan Capital Partners LP (“Politan LP”), Politan Capital Offshore Partners LP (“Politan Offshore” and, collectively with Politan Master Fund and Politan LP, the “Politan Funds”), Quentin Koffey, Matthew Hall, Aaron Kapito (all of the foregoing persons, collectively, the “Politan Parties”), William Jellison and Darlene Solomon (such individuals, collectively with the Politan Parties, the “Participants”).
  • 1 Declaration of David F. Larcker in Support of Politan’s Opposition to Masimo’s Motion for Preliminary Injunction.
  • 3 Declaration of Najeeb Ali of Centerview Partners in Support of Politan’s Opposition to Masimo’s Motion for Preliminary Injunction.

Masimo’s Future Depends on Vote at September 19 Annual Meeting

Retrieved on: 
Monday, September 9, 2024
Biotechnology, Medical Devices, Biometrics, Health, Health Technology, Risk, Sale, Head, RealClearPolitics, GAAP, Consultant, Patent, Internet, Masimo, Patient safety, Senior advisor, Growth, EPS, ALL, Face, Partnership, GOLD, MASI, Corporation, Annual general meeting, DEI Holdings, Letter, Patient, Pediatrics, Medtronic, Baylor University Medical Center, Loma Linda University, Physician, Policy, Management

Stockholders of record as of the close of business on August 12, 2024 are entitled to vote at the Annual Meeting.

Key Points: 
  • Stockholders of record as of the close of business on August 12, 2024 are entitled to vote at the Annual Meeting.
  • We are appealing to you because leadership matters and we believe the upcoming vote will determine the future value of your investment.
  • If you received this letter by email, you may also vote by pressing the “VOTE NOW” button in the accompanying email.
  • To enable your votes to be validly counted for the 2024 Annual Meeting, you must resubmit your vote on the updated GOLD proxy card or voting instruction form attached to the revised proxy statement for the 2024 Annual Meeting now scheduled to be held on September 19, 2024.

Masimo Urges Stockholders to Vote “FOR” Only Masimo’s Director Nominees, Joe Kiani and Christopher Chavez, on the Updated GOLD Proxy Card Today

Retrieved on: 
Tuesday, September 3, 2024
Medical Devices, Health, GOLD, Internet, ALL, Risk, Character, Acquisition, Masimo, Apple, MASI, Corporation, Committee, Special, Disclosure, Common stock, Letter, Schedule, Algorithm, Annual, Investment, Capital, Annual general meeting, Medtronic, Employment, Comment, Security (finance), Failure, Common, Person, Human, AlphaSights, Proxy, Knowledge, Growth, Next wave, Patent, Entrust, Form, Lawyer, Ethics, Cryptocurrency

Masimo is urging stockholders to vote “FOR” the Company’s director nominees, Joe Kiani and Christopher Chavez, on the updated GOLD proxy card to protect the Company and the value of their investment.

Key Points: 
  • Masimo is urging stockholders to vote “FOR” the Company’s director nominees, Joe Kiani and Christopher Chavez, on the updated GOLD proxy card to protect the Company and the value of their investment.
  • We urge you to vote “FOR” Masimo’s director nominees, Joe Kiani and Christopher Chavez, on the updated GOLD proxy card to protect Masimo’s future and your investment.
  • Simply follow the easy instructions on the enclosed updated GOLD proxy card to vote by internet or by signing, dating, and returning the updated GOLD proxy card in the postage-paid envelope provided.
  • Please be sure to vote ALL your accounts using the updated GOLD proxy card relating to each account.

March of Dimes Announces Executive Leadership Changes to Advance US Maternal and Infant Health Initiatives

Retrieved on: 
Tuesday, August 27, 2024
Death, Kaiser Permanente, FDA, FACOG, Obstetrics, MPH, Growth, Masimo, Infant, Medicine, Interim, Trustee, Preterm birth, HCA Healthcare, Education, University, Business, Pregnancy, Health equity, NICU, Marketing, Research, Aspirin, Gynaecology, News, Pre-eclampsia, Management

ARLINGTON, Va., Aug. 27, 2024 /PRNewswire/ -- March of Dimes, the leading non-profit dedicated to improving maternal and infant health, is pleased to announce the appointment of Cindy Rahman as Interim President and Chief Executive Officer and Amanda P. Williams, MD, MPH, FACOG as Interim Chief Medical Officer. These leadership changes mark an exciting chapter for the organization as it continues its mission to end preventable maternal health risks and death, preterm birth, and infant death, while closing the health equity gap.

Key Points: 
  • These leadership changes mark an exciting chapter for the organization as it continues its mission to end preventable maternal health risks and death, preterm birth, and infant death, while closing the health equity gap.
  • "Understanding our strengths and recognizing our opportunities will allow us to continue to build on the strong foundation we have in place across the organization.
  • These executive changes come at a time of significant positive momentum for March of Dimes.
  • The March of Dimes Innovation Fund is a venture philanthropy initiative that will use donated funds to invest in early-stage companies to address the most pressing maternal and infant health challenges.

Masimo Has the Right Leadership and Strategy to Drive Long-Term Value Creation

Retrieved on: 
Monday, August 26, 2024
Technology, Medical Devices, Finance, Other Technology, Health Technology, Professional Services, Audio, Video, Other Health, Hardware, Health, Corporation, Multimedia, FDA, Masimo, MASI, GOLD, Annual general meeting, Growth, ALL, EPS, Letter, Patent, Internet, Risk, Perioperative medicine, Population health, Patient, Outline, GAAP, Morgan Stanley, Management

WHY THIS VOTE MATTERS: Preserving our leadership team and engineers is paramount to our continued success.

Key Points: 
  • WHY THIS VOTE MATTERS: Preserving our leadership team and engineers is paramount to our continued success.
  • Over the past 35 years, Masimo has delivered outstanding innovations and established itself as a partner of choice for today’s leading healthcare providers.
  • Customer relationships with our senior management are key to maintaining our portfolio expansion strategy while increasing market share gains.
  • Masimo today is advancing a clear value creation strategy as we continue to gain market share, reduce costs, secure FDA approvals and innovate across both new and existing products.

Masimo is Executing a Successful Strategy to Deliver Long-Term, Sustainable Growth

Retrieved on: 
Thursday, August 15, 2024
Technology, Medical Devices, Finance, Other Technology, Health Technology, Professional Services, Audio, Video, Other Health, Hardware, Health, Physician, Ecosystem, FDA, Hospital, Development, GOLD, Letter, Disease, ALL, Masimo, MASI, Annual general meeting, Growth, Mortality, Patient, Noise, Name, Health care, Death, Sepsis, Pulse oximetry, Internet, Trauma, Security (finance), Corporation, Sale, Pharmaceutical industry

In connection with the filing of its revised definitive proxy statement, Masimo is mailing a letter to stockholders highlighting the successful execution of its strategy to deliver long-term, sustainable growth and urging stockholders to vote “FOR” the Company’s director nominees, Joe Kiani and Christopher Chavez, on the updated GOLD proxy card.

Key Points: 
  • In connection with the filing of its revised definitive proxy statement, Masimo is mailing a letter to stockholders highlighting the successful execution of its strategy to deliver long-term, sustainable growth and urging stockholders to vote “FOR” the Company’s director nominees, Joe Kiani and Christopher Chavez, on the updated GOLD proxy card.
  • Earlier this month, we reported strong second quarter results that underscore our business momentum and position Masimo to deliver sustainable growth.
  • With our ongoing successful execution of our core business, electing Politan’s nominees would most certainly derail our sustainable growth trajectory.
  • Our consistently strong contracting over the last several quarters points to a bright future with new levels of growth opportunity.